Page 2 - ஜான் ட்‌ஸை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஜான் ட்‌ஸை. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஜான் ட்‌ஸை Today - Breaking & Trending Today

Novartis announces iptacopan met Phase II study primary endpoint in rare kidney disease IgA nephropathy (IgAN)

Novartis announces iptacopan met Phase II study primary endpoint in rare kidney disease IgA nephropathy (IgAN)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Czech Republic , United States , Isabella Zinck , Thomas Hungerbuehler , Van Praet , Jonathan Barratt , Samir Shah , Jamie Bennett , Julie Masow , Sloan Simpson , Phil Mcnamara , John Tsai , J Nephrol Renovasc , University Of Leicester , Head Of Global Drug Development , Novartis Institutes For Biomedical Research , Novartis Us External Communications , Exchange Commission , European Medicines Agency , Renal Medicine , Leicester General , Global Drug Development , Chief Medical Officer , Therapy Designation , Novartis Institutes , Biomedical Research ,

Novartis Pharma AG: Novartis announces iptacopan met Phase II study primary endpoint in rare kidney disease IgA nephropathy (IgAN)

Novartis Pharma AG: Novartis announces iptacopan met Phase II study primary endpoint in rare kidney disease IgA nephropathy (IgAN)
3-7
C3 glomerulopathy
Basel,
2
1 - Novartis today announced Phase II primary endpoint data showing investigational iptacopan (LNP023) - a first-in-class, oral, targeted factor B inhibitor - reduced protein in the urine (proteinuria), an increasingly recognized surrogate marker correlating with progression to kidney failure
2, and showed promise in stabilizing kidney function in patients with IgA nephropathy (IgAN)
1. The data were presented at the 58
th ERA-EDTA Congress held virtually from June 5-8, 2021.
In the Phase II study (NCT03373461), patients (n=112) with IgAN were randomized to placebo or different doses of iptacopan ....

Czech Republic , United States , Isabella Zinck , Thomas Hungerbuehler , Van Praet , Jonathan Barratt , Samir Shah , Jamie Bennett , Julie Masow , Sloan Simpson , Phil Mcnamara , John Tsai , J Nephrol Renovasc , University Of Leicester , Head Of Global Drug Development , Novartis Institutes For Biomedical Research , Novartis Us External Communications , Exchange Commission , European Medicines Agency , Renal Medicine , Leicester General , Global Drug Development , Chief Medical Officer , Therapy Designation , Novartis Institutes , Biomedical Research ,

Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): Novartis announces iptacopan met Phase II study primary endpoint in rare kidney disease IgA nephropathy (IgAN)

Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis announces iptacopan met Phase II study primary endpoint in rare kidney disease IgA nephropathy (IgAN) ....

Czech Republic , United Kingdom , United States , Isabella Zinck , Thomas Hungerbuehler , Van Praet , Jonathan Barratt , Samir Shah , Jamie Bennett , Julie Masow , Sloan Simpson , Phil Mcnamara , John Tsai , J Nephrol Renovasc , University Of Leicester , Head Of Global Drug Development , Novartis Institutes For Biomedical Research , Novartis Us External Communications , Exchange Commission , European Medicines Agency , Renal Medicine , Leicester General , Global Drug Development , Chief Medical Officer , Therapy Designation , Novartis Institutes ,

Novartis' nuclear therapy helps men with prostate cancer live longer - data

3 minute read
The company s logo is seen at the new cell and gene therapy factory of Swiss drugmaker Novartis in Stein, Switzerland, November 28, 2019. REUTERS/Arnd Wiegmann/File Photo
Men with a deadly form of advanced prostate cancer who failed other treatments survived four months longer after getting an experimental, tumour-targeting radiation therapy from Swiss drugmaker Novartis (NOVN.S), data released on Thursday showed.
The company s Lu-PSMA-617 therapy boosted median overall survival (OS) to 15.3 months in patients with metastatic castration-resistant prostate cancer, according to data released at the 2021 American Society of Clinical Oncology annual meeting.
That compared with 11.3 months for men who got standard care. ....

New York , United States , Memorial Sloan Kettering Cancer Center , Michael Morris , John Tsai , Thomson Reuters Trust Principles , American Society Of Clinical Oncology , Clinical Oncology , Thomson Reuters Trust , M Ez , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , நினைவகம் ஸ்லோன் கெட்டரிங் புற்றுநோய் மையம் , மைக்கேல் மோரிஸ் , ஜான் ட்‌ஸை , தாம்சன் ராய்ட்டர்ஸ் நம்பிக்கை ப்ரிந்ஸிபல்ஸ் , அமெரிக்கன் சமூகம் ஆஃப் மருத்துவ புற்றுநோயியல் , மருத்துவ புற்றுநோயியல் , தாம்சன் ராய்ட்டர்ஸ் நம்பிக்கை ,

Novartis reports one year results of Phase III MERLIN study evaluating Beovu® every four week dosing and provides update on Beovu clinical program | Antibodies

Novartis reports one year results of Phase III MERLIN study evaluating Beovu® every four week dosing and provides update on Beovu clinical program ....

United States , United Kingdom , Lookeren Campagne , Beovu Basel , John Tsai , World Health Organization , Global Head Of Drug Development , Health Qual Life Outcomes , Canadian Drug Expert Committee Recommendation , National Eye Institute , National Health Insurance Pricing , European Society Of Retina Specialists , Canadian Agency For Drugs , Nj Novartis Pharmaceuticals Corporation , Technologies In Health , Lancet Glob Health , United Statesi May , Global Head , Drug Development , Chief Medical Officer , North America , Age Related Macular Degeneration , Retinal Vascular , East Hanover , Pharmaceuticals Corporation , Double Masked Trials ,